PILL BURDEN, DRUG CLASS DISTRIBUTION AND FINANCIAL BURDEN FOR BUYING MEDICINES IN DIFFERENT MODALITIES OF CHRONIC KIDNEY DISEASE PATIENTS: CROSS-SECTIONAL STUDY

Objective: The objective of the study was to assess the pill burden (PB), drug class distribution and financial burden for buying medicines in different treatment modalities of chronic kidney disease (CKD) patients. Methods: A prospective, cross-sectional study was performed in 244 CKD patients and they were divided into 4 groups as follows: pre-dialysis patients (stages 1-5) as group 1, hemodialysis (HD) patients as group 2, peritoneal dialysis (PD) patients as group 3 and renal transplant recipient (RTR) patients as group 4. Data was collected in pre-designed form through direct patient interaction.Results: Out of 244 CKD patients, PB considering the total number of pills/d in different modalities is 12±5 in pre-dialysis, 10±3 in HD, 13±5 in PD, 14±7 in RTR and for the number of drug classes/d in different modalities is 7±3 in pre-dialysis, 7±2 in HD, 8±3 in PD and 9±3 in RTR. On average mean PB in a number of pills/d is 12±5 and number of drug classes/d is 8±3. Among all the patients, the RTR individuals are having high medicinal expenditure in comparison to the other modalities.Conclusion: PB for the number of pills/d is highest in RTR and almost similar in different modalities. Great improvement in reducing the PB as well as financial burden directly or indirectly improves the patient compliance as well as the quality of life

PILL BURDEN, DRUG CLASS DISTRIBUTION AND FINANCIAL BURDEN FOR BUYING MEDICINES IN DIFFERENT MODALITIES OF CHRONIC KIDNEY DISEASE PATIENTS: CROSS-SECTIONAL STUDY

Objective: The objective of the study was to assess the pill burden (PB), drug class distribution and financial burden for buying medicines in different treatment modalities of chronic kidney disease (CKD) patients. Methods: A prospective, cross-sectional study was performed in 244 CKD patients and they were divided into 4 groups as follows: pre-dialysis patients (stages 1-5) as group 1, hemodialysis (HD) patients as group 2, peritoneal dialysis (PD) patients as group 3 and renal transplant recipient (RTR) patients as group 4. Data was collected in pre-designed form through direct patient interaction.Results: Out of 244 CKD patients, PB considering the total number of pills/d in different modalities is 12±5 in pre-dialysis, 10±3 in HD, 13±5 in PD, 14±7 in RTR and for the number of drug classes/d in different modalities is 7±3 in pre-dialysis, 7±2 in HD, 8±3 in PD and 9±3 in RTR. On average mean PB in a number of pills/d is 12±5 and number of drug classes/d is 8±3. Among all the patients, the RTR individuals are having high medicinal expenditure in comparison to the other modalities.Conclusion: PB for the number of pills/d is highest in RTR and almost similar in different modalities. Great improvement in reducing the PB as well as financial burden directly or indirectly improves the patient compliance as well as the quality of life